International Conference on Advances in Molecular Diagnostics and Precision Medicine (AMDP - 2022)

• AMDP-2022 conference is unique in attracting  Nobel Laureates, Distinguished Doctors, Eminent Scientists, and Investors from around the world to discuss the latest advances in medicine and diagnostic care.

 

Chennai, September 16, 2022: The International Conference on Advances in Molecular Diagnostics and Precision Medicine (AMDP) began on 15th September 2022 at Anna University, Chennai and will continue till 17th September. The conference revolves around various facets of Molecular Diagnostics and Precision Medicine as the major area and Drug discovery and Development and Nanotechnology as parallel sessions. 

Youtube Video👇

The conference has attracted over 800 delegates that include experts from the field of Molecular Diagnostics, Personalized Cancer Therapies, Infectious Diseases, Rare Diseases, Bio-Nanotechnology, etc. Apart from insights from some of the best minds in medicine and medical technology, the conference also hosts investors who are interested to explore emerging technologies.

AMDP 2022  also witnesses product launches by MagGenome Technologies Pvt Ltd. They have specifically strengthened the sector of medical diagnostics by launching XpressAutoMag range of products for DNA and RNA extraction from biological samples. These unique products will fill the gap in the current market by providing DNA extraction using MagGenome’s proprietary Magnetic Nano Particle (MNP) technology that will improve efficiency, and reduce time and cost for the general public. This has applications in doing faster tests for the general public as well as for large-scale industries. 

DNA and RNA extraction using MNP technology will improve yield, purity and quality in comparison to the currently existing solutions in India. Additionally, MagGenome’s flexible, automated nucleic acid extraction platform will provide stable and reproducible results at a low cost. This technology will effectively avoid cross-contamination and ensure high quality of extracted nucleic acids and will further enhance global applications in research and diagnostic capabilities in the field of molecular diagnostics and genomics. This will also strengthen ‘Made in India products for the World’ in the clinical diagnostics sector. 

(L to R) Sam Santosh, Chairman, SGRF & SciGenom Labs; Dr RamChand CN, Cofounder, CEO, CSO, MagGenome Technologies Pvt Ltd; Dr.Aniruddha Bhati, Sr.Scientist, Mag Genome

Several speakers and participants from Life Sciences and Diagnostics companies like MagGenome Technologies Pvt Ltd, KMTC, KLIP, Genes2me, Neuberg diagnostics, Nanostrings, Premas Biotech, Levim Biotech, SPT Labtech, ThermoFisher Scientific, Bioengineering, GenNext Genomics Pvt Ltd., iOrbitz and Institutes like CCMB, IGIB, NCBS, CDFD, AIIMS, and CHARUSAT will attend the event. The Patron of the conference is Mr.Sam Santhosh. Dr.CN Ramchand and Dr.S Meenakshi Sundaram are the Conference Conveners and Dr.Aniruddha Bhati is the Organising Secretary.

AMDP-2022 is the first of its kind, organised by SciGenom Research Foundation (SGRF), a not-for-profit organization, that works toward promoting Science in India through research and education, with a specific focus on Molecular Diagnostics and Precision Medicine. AMDP hosted well-known dignitaries in the field coming together to augment their research activities with Indian scientists and companies as partners. This will provide a much-needed boost to the research in these sectors that shows promise to deal with communicable and non-communicable diseases around the world. The program also includes a ‘Healthcare Investors Panel discussion’ which will be moderated by Mr Sam Santhosh, a well-known Healthcare Investor and Chairman of SciGenom group of companies. The other investors that are present at the event include 3ONE4 Capital, TPG, Eight Roads, Leapfrog investments and Sofina to list a few.

The Conference will also provide student scholarships, poster awards, young scientist awards and lifetime achievement awards to deserving candidates and proven performers in the field. 

****